Search results
Results from the WOW.Com Content Network
This is a shortened version of the first chapter of the ICD-9: Infectious and Parasitic Diseases. It covers ICD codes 001 to 139. The full chapter can be found on pages 49 to 99 of Volume 1, which contains all (sub)categories of the ICD-9. Volume 2 is an alphabetical index of Volume 1.
This is a shortened version of the sixth chapter of the ICD-9: Diseases of the Nervous System and Sense Organs. It covers ICD codes 320 to 389 . The full chapter can be found on pages 215 to 258 of Volume 1, which contains all (sub)categories of the ICD-9.
List of ICD-9 codes 140–239: neoplasms; List of ICD-9 codes 240–279: endocrine, nutritional and metabolic diseases, and immunity disorders; List of ICD-9 codes 280–289: diseases of the blood and blood-forming organs; List of ICD-9 codes 290–319: mental disorders; List of ICD-9 codes 320–389: diseases of the nervous system and sense organs
Meningococcal vaccine refers to any vaccine used to prevent infection by Neisseria meningitidis. [9] Different versions are effective against some or all of the following types of meningococcus: A, B, C, W-135, and Y. [ 9 ] [ 10 ] The vaccines are between 85 and 100% effective for at least two years. [ 9 ]
Penbraya is a pentavalent conjugate vaccine developed by Pfizer for the prevention of invasive meningococcal disease in people 10 through 25 years of age. [4] Invasive meningococcal disease, caused by the bacterium Neisseria meningitidis, can lead to serious conditions such as meningitis (inflammation of the brain and spinal cord lining) and sepsis. [5]
Facebook posts claim a new medical diagnosis code for people who decline the vaccine will be used to determine who goes to "education camps." Facebook posts claim a new medical diagnosis code for ...
The first vaccine to prevent meningococcal serogroup B (meningitis B) disease was approved by the European Commission on 22 January 2013. [12] Vaccines offer significant protection from three to five years (plain polysaccharide vaccine Menomune, Mencevax and NmVac-4) to more than eight years (conjugate vaccine Menactra). [13] [14]
NmVac4-A/C/Y/W-135 is the commercial name for a polysaccharide vaccine that protects against meningococcal meningitis caused by Neisseria meningitidis, specifically the serotypes A, C, Y, and W-135. This vaccine is part of a broader group of meningococcal vaccines.